secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001140361-24-036944
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Q2 net loss $7.8M ($0.30/sh); cash $41.4M; VEGA-3 recruiting for presbyopia
--------------------------------------------------------------------------------

- Net loss $7.8M ($0.30/sh) vs $5.0M ($0.24) in Q2 2023; revenue from collaborator license $1.1M vs $3.7M.
- Cash $41.4M provides runway into mid-2025; R&D spend $6.1M (+30% YoY) driven by APX3330 manufacturing.
- VEGA-3 Phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia now recruiting; topline 2025.
- LYNX-2 Phase 3 study for dim light disturbances enrollment strong; LYNX-3 study planned for 2024.
- Discussions with FDA ongoing for APX3330 Special Protocol Assessment in diabetic retinopathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124036944/0001140361-24-036944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124036944/ef20033986_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer